v3.26.3
EARNINGS (LOSS) PER SHARE (Tables)
9 Months Ended
Sep. 30, 2026
Earnings Per Share [Abstract]  
SCHEDULE OF BASIC AND DILUTED EARNINGS PER SHARE

The following table reconciles net income attributable to LifeMD, Inc. common stockholders from continuing operations and discontinued operations to basic and diluted earnings per share:

 

   2026   2025   2026   2025 
   Three Months Ended September 30,   Nine Months Ended September 30, 
   2026   2025   2026   2025 
Net loss from continuing operations  $(4,469,713)  $(4,574,977)  $(20,585,088)  $(10,007,701)
Less: Preferred stock dividends   (776,563)   (776,563)   (2,329,688)   (2,329,688)
Net loss from continuing operations attributable to LifeMD, Inc. common stockholders   (5,246,276)   (5,351,540)   (22,914,776)   (12,337,389)
Net income from discontinued operations   -    935,013    -    4,821,519 
Less: Net income attributable to noncontrolling interests of discontinued operations   -    249,462    -    1,286,382 
Net income from discontinued operations attributable to LifeMD, Inc. common stockholders   -    685,551    -    3,535,137 
Net loss attributable to LifeMD, Inc. common stockholders  $(5,246,276)  $(4,665,989)  $(22,914,776)  $(8,802,252)
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES

The following table discloses the securities that were not included in the computation of diluted earnings (loss) per share as their inclusion would have been anti-dilutive:

 

   2026   2025   2026   2025 
  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
   2026   2025   2026   2025 
RSUs and RSAs   852,056    1,619,557    522,623    1,357,172 
Stock options   110,842    345,504    187,616    440,877 
Warrants   424,349    622,263    438,937    979,360 
Convertible long-term debt   -    -    -    671,141 
Total   1,387,247    2,587,324    1,149,176    3,448,550